About Peter Moss Leukemia AI Research
In 2018 my grandfather, Peter Moss, was diagnosed terminally ill with Acute Myeloid Leukemia. One month before he was diagnosed he had an all clear blood test, with no signs of Acute Myeloid Leukemia, I was convinced that there must have been signs in that blood test that could have given a clue to what was coming the following month.
I had experience previous experience with using Artificial Intelligence for breast cancer detection through the Breast Cancer AI project, and I wanted to see if I could use this experience to help with Acute Myeloid Leukemia.
I created the Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project, and set out to build a team that would work on open-source classifiers for Leukemia with the goals of early detection.
Peter Moss Leukemia AI Research Student Program
During 2019, the project attracted researchers and developers from throughout the globe and we started a free student program, the Peter Moss Leukemia AI Research Student Program. The purpose of the student program was to give students a way to work with developers and medical experts on projects that gave them some real world experience of developing applications for medical use cases.
Estela Cabezas joined the student program in 2019 to help her get some insight into artificial intelligence for medical applications. Through the Intel Innovators Program, Estela presented our project at Embedded World 2019, Intel Dev Affinity Day 2019 and Codemotion 2019, and was able to use our project as case study in her thesis: Applied Analytics for clinical decision support.
Embedded World, Nuremberg, Germany
In 2019 we got the opportunity to present the Peter Moss Acute Lymphoblastic Leukemia Detection System 2019 at the Intel booth at Embedded World 2019, Nuremberg, Germany.
Myself and Estela Cabezas visited Germany to join Intel at their booth to present the project, demonstrating the use of Intel technologies for detection of Acute Lymphoblastic Leukemia.
The event was Estela's first time demonstrating at a technology event and brought some medical experience to our demonstration. We spoke with many people from different backgrounds that were interested in the project and were thankful to Intel for the great positioning of our stand.
Intel Dev Affinity Day 2019, Munich, Germany
The team was invited to attend the invite only event Intel Developer Affinity Day at the Intel IoT Lab in Munich in May 2019.
The event was for Intel Software Innovators and Student Ambassadors to meet with Intel staff and executives.
Estela Cabezas represented our team at the event and presented a talk about the Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project.
Codemotion Madrid 2019, Madrid, Spain
The team was invited to give a speakership @ CodeMotion in Madrid in the Code Motion Diversity In Tech Topic.
Estela Cabezas represented our team, giving a talk on the structure and recent developments of the project.
This was Estela's second event as an official Intel Software Innovator representing the Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project.
Intel AI Devmesh Award
The Peter Moss Acute Lymphoblastic Leukemia Detection System 2019 project was based on one of my open-source projects, GeniSysAI and is a featured project on Intel Devmesh, the Intel Developer Zone social network.
At the end of 2019 the project was voted 1st in Europe out of 4 projects, and awarded the Intel® DevMesh AI Spotlight Award which was a new designation granted by Intel recognizing inspiring and breakthrough Artificial Intelligence projects in development from the Intel software community.
Peter Moss Passed Away
In August 2019, after battling AML for one day short of a year since being terminally diagnosed, my grandfather sadly passed away. In his memory the team committed to the fight against leukemia & other cancers in his name.
Our goal remains to continue providing researchers, students, developers and medical professionals a way to contribute and collaborate towards finding ways to battle Leukemia with technology, as well as giving the public a platform to find open information about leukemia, and speak with our team and professionals.
During 2020 I volunteered full time to building the core platform that we would use to manage our team and projects, as well as focusing on building the team itself.
2020, The Pandemic
Our team was working on using AI for analysing COVID-19 data since the early days of the pandemic, and not long after Peter Moss COVID 19 AI Research Project was created as a research project with Peter Moss Leukemian AI Research.
On March 28th I was admitted to Parc Tauli Hospital, Sabadell as a potential COVID-19 patient. I was confined in the ICU reception with COVID 19 & potential COVID 19 patients due to the lack of beds available in the hospital. I was concerned with the amount of time that hospital staff were being exposed to the virus.
Partnership with PlamenLancaster
In May we teamed up with Plamenlancaster: Professor Plamen Angelov from Lancaster University/ Centre Director @ Lira, & his researcher, Eduardo Soares PhD. PlamenLancaster pioneered eXplainable Deep Learning and created the SARS-COV-2 Ct-Scan Dataset, a large dataset of CT scans for SARS-CoV-2 (COVID-19) identification. Our team are working on open-source, real-world diagnosis systems based on xDNN and the SARS-COV-2 Ct-Scan Dataset to help fight the COVID-19 pandemic.
Our team made a number of open-source classifiers for detecting COVID 19 based on PlamenLancaster's dataset. These classifiers achieved high results and are available for free on the Peter Moss COVID 19 AI Research Project Github account.
Registering As A Non-Profit
At the beginning of 2020, my plans were to take our research projects to the next stage by registering as a non-profit. In June 2020 Asociación de Investigacion en Inteligencia Artificial Para la Leucemia Peter Moss was registered in memory of my grandfather. We are now a team of 11 volunteers and have published over 20 Github repositories through our research projects: Peter Moss Leukemia AI Research, Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project & Peter Moss COVID-19 AI Research Project.
Pilot Project with Melanoscan
In October 2020, we were excited to start a new collaboration with Melanoscan, a biotechnology company in the United States working on Skin Cancer.
With Melanoscan we had the opportunity to take HIAS through it's first pilot project giving our team the first step into the medical industry. The partnership is going very well and we have a lot of projects in the pipeline with Melanoscan.
The Future Of Peter Moss Leukemia AI Research
We now have an amazing team working on our student program which we will be launching early in 2021 with the goals of helping students with some real world experience of creating Artificial Intelligence and Internet of Things projects for medical use cases.
I am very proud of how far our team have come since 2018, we remain dedicated to the fight against leukemia and other cancers in memory of my grandfather, and we hope to play to a part in helping families that go through the experiences my family went through living with Acute Myeloid Leukemia.